Abstract：Objective To investigate the survival status of people living with HIV/AIDS (PLHIV) receiving antiretroviral therapy (ART) and its influencing factors in Shanghai, and to evaluate the effect of ART. Methods A retrospective cohort study was used to analyze the follow-up data about PLHIV receiving ART in Shanghai from 2005 to 2017. The follow-up was completed on December 31, 2018. Life table method was used to calculate the survival rate of PLHIV with ART, and Cox proportional hazards regression model was employed to explore associated factors of survival time. Results The average age of 9,251 PLHIV enrolled in this study was (38.2±13.2) years, and most were males (8,447 cases, 91.3%) and homosexual transmission (5,536 cases, 59.8%). The median survival time was 21.9 months. Deaths due to AIDS added up to 194. The accumulated survival rates of 1-, 3-, 5- and 10-year after initiating ART were 0.983, 0.979, 0.972 and 0.963, respectively. According to Cox proportional hazards regression analysis results, the factors affecting the survival time of PLHIV receiving ART were age, baseline CD4+ T-cell count, initial ART regimen, adjustment of the regimen and transmission route (all P<0.05). Conclusions The effect of ART in PLHIV in Shanghai is remarkable. ART coverage should be extended, and early ART initiation should be applied to PLHIV. Supervision of ART effect and timely adjustment of the regimen are crucial to improving survival quality of PLHIV.
[1] Zhang F, Dou Z, Yu L, et al. The effect of highly active anti-retroviral therapy on mortality among HIV—infected former plasma donors in China[J].Clin Infect Dis, 2008, 47(6):825-833. [2] Rossi SM, Maluf EC, Carvalho DS,et al. Impact of antiretroviral-therapy under different treatment regimens[J].Rev Panam Salud Publica, 2012, 32(2):117-123. [3] INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection[J].N Engl J Med, 2015, 373(9):795-807. [4] 国家卫生健康委员会. 国家卫生健康委员会2018年11月23日例行新闻发布会散发材料之一:我国艾滋病防治工作进展[EB/OL].(2018-11-23)[2020-02-01]. http://www.nhc.gov.cn/wjw/xwdt/201811/5fe377b577d04d369a057970c0f816d1.shtml. [5] 张福杰.国家免费艾滋病抗病毒治疗手册[M].第3版.北京:人民卫生出版社, 2012:15-18. [6] 陈婧,徐敏,赵啸,等. 北京市2005—2015年艾滋病抗病毒治疗患者生存及其影响因素[J]. 中华疾病控制杂志,2018,22(12):1225-1228. [7] 李西婷,罗艳,程洁,等. 杭州市2004—2014年艾滋病患者抗病毒治疗的分析[J]. 中华临床感染病杂志,2017,10(1):20-25. [8] 周琳,吴琼海,沈伟伟,等. 浙江省台州市接受抗病毒治疗的艾滋病患者生存分析[J]. 中华疾病控制杂志,2013,17(12):1049-1051. [9] 郑武,笪琴,张薇,等. 湖北省2003—2015年艾滋病抗病毒治疗患者生存状况分析[J]. 中国预防医学杂志,2017,18(12):885-889. [10] 姚书杰,吕娅妮,王莉,等. 辽宁省2003—2015年7 255例艾滋病抗病毒治疗患者的生存分析[J]. 中华疾病控制杂志,2016,20(12):1203-1207. [11] 崔倩, 俞文祥, 祁耀, 等. 盐城市2005—2015年艾滋病抗病毒治疗患者生存分析[J].实用预防医学,2018,25(5):538-542. [12] 何海,李巧巧,周超,等. 重庆市2004—2013年艾滋病抗病毒治疗患者生存时间及影响因素分析[J]. 中华疾病控制杂志,2016,20(1):21-25. [13] Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United Stated and Canada [J]. PLoS One, 2013,8(12):e81355. [14] Zhang F, Dou Z, Yu L, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China[J]. Clin Infect Dis,2008,47(6):825-833. [15] 曾亮,马烨,豆智慧,等. 我国艾滋病抗病毒治疗标准调整前后治疗病人生存情况研究[J]. 中国艾滋病性病,2016,22(7):488-492. [16] 付笑冰,林鹏,刘勇鹰,等. 广东省艾滋病患者抗病毒治疗后生存时间分析[J]. 华南预防医学,2009,35(3):1-4. [17] Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies[J].Lancet, 2002,360(9327):119-129. [18] Velen K, Lewis JJ, Charalambous S, et al. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study[J]. PLoS One, 2013,8(5):e64459.
2020, Vol. 27 
